October 10th 2025
Can you guess the diagnosis?
October 6th 2025
The once-daily, steroid-free cream can be used anywhere on the body for treatment, and for any duration, according to Arcutis.
October 3rd 2025
Watch our FDA pipeline news recap for the month of September 2025, as well as a preview of a key PDUFA date in October.
Ingrid Polcari, MD, highlights concerns with teen skin care trends and emphasizes simple, age-appropriate routines tailored to patient needs.
October 2nd 2025
Ingrid Polcari, MD, discusses acne severity, treatment options, and the importance of persistence and open discussion in pediatric care.
FDA approves roflumilast foam 0.3% for scalp, body psoriasis
The once-daily, steroid-free topical is now approved to treat plaque psoriasis of the scalp and body in patients aged 12 years and older.
FDA approves pz-cel for recessive dystrophic epidermolysis bullosa
The decision makes pz-cel the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.
FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up
The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU.
FDA approves maralixibat tablet formulation for ALGS and PFIC
In the United States, maralixibat (Livmarli; Mirum Pharmaceuticals) is approved to treat both ALGS and PFIC, now in liquid and tablet formulations.
JNJ-2113 for plaque psoriasis demonstrates clear skin in 75% of adolescents
“Data from the Phase 3 ICONIC LEAD subgroup analysis demonstrate impressive efficacy rates, showing the promise of this novel therapeutic option," said Lawrence Eichenfield, MD.
Uncharacteristic skin findings in a toddler with a history of dermatitis
The patient’s medical history included several episodes of mild diaper dermatitis and erythematous rashes during periods of teething.
Full case: 21-month-old with history of “skin tags” on her gluteal cleft
Read the full case presentation of a 21-month-old with a history of "skin tags" involving her gluteal cleft,noted at birth.
A preview of the April Allergy Awareness issue of Contemporary Pediatrics
Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April, 2025, issue of Contemporary Pediatrics, with a special focus on pediatric allergy awareness.
Q1 2025: A recap of the top headlines and interviews
View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.
Diagnose this 21-month-old with history of “skin tags” on her gluteal cleft
Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.
Weekly review: Multiple FDA approvals, expert discussions and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
5 pediatric FDA decisions to watch for in Q2 2025
A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.
Peter Lio, MD, highlights recent lebrikizumab data to treat atopic dermatitis
Peter Lio, MD, offers thoughts on recent atopic dermatitis data reported for lebrikizumab.
Full case: Linear eruption on the leg of 9-year-old girl
What's the diagnosis of this linear eruption on an adolescent girl's leg?
Poll: What's the diagnosis of this linear eruption on the leg of a 9-year-old girl?
Take your best guess and try to diagnose this 9-year-old girl's linear eruption on the back of her left thigh and leg. Stay tuned for the full case presentation and correct diagnosis!
Baricitinib shows promise for adolescent alopecia areata in phase 3 trial
The study, known as BRAVE-AA-PEDS, was sponsored by Eli Lilly and Company and involved 257 adolescents aged 12 to under 18 years.
Tapinarof cream 1% demonstrates positive long-term results for atopic dermatitis in patients 2 years and up
The newest tapinarof results were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
Lebrikizumab improves atopic dermatitis symptoms in patients previously on dupilumab
Lebrikizumab improves itch, sleep interference, and skin pain in atopic dermatitis patients previously treated with dupilumab, offering a new treatment option.
Weekly review: Roflumilast 0.05% sNDA accepted, palforzia launches for US toddlers
FDA accepts roflumilast cream 0.05% sNDA for children with atopic dermatitis
The application is for children aged 2 to 5 years with mild-to-moderate atopic dermatitis.
Roflumilast cream 0.05% demonstrates eczema area severity, itch improvement for pediatric atopic dermatitis
Nearly 40% of children treated with roflumilast cream 0.05% achieved a 75% improvement in EASI-75.
Full case study: Urticarial rash in a 9-hours-old male
On exam, the patient is found to have circular, slightly raised, blanching, erythematous papules on the lower extremities and abdomen.
Puzzler poll: Urticarial rash in a 9-hours-old male
Can you diagnose this patient in our most recent puzzler poll?
Weekly review: Several key FDA approvals, new puzzler case, and more
EN-374 granted rare pediatric disease, orphan drug designations for chronic granulomatous disease
Ensoma's lead program, EN-374, has been granted a pair of FDA designations for the treatment of X-linked chronic granulomatous disease.
A green nail after trauma in an 8-year-old boy
His mother reported that the nail had developed a green discoloration and had begun to detach approximately 1 week prior to the visit.
Weekly review: New delgocitinib data for eczema, FDA action items, more
FDA grants rezpegaldesleukin fast track to treat moderate, severe atopic dermatitis
The investigational biologic targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells.
Debunking myths about diet and acne
A look into nutrition's role in acne care, highlighted by Colleen Sloan, PA-C, RDN.
Phase 3: Delgocitinib improves chronic hand eczema in adolescents
The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial.
